Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

GRP-78 Secreted by Tumor Cells Blocks the Anti-Angiogenic Activity of Bortezomib.

Johann Kern, Gerold Untergasser, PhD, Christoph Zenzmaier, Bettina Sarg, Gunther Gastl, Prof., Dr., Eberhard Gunsilius, M.D., Michael Steurer, MD

Blood (2009) 114 (22): 4805.

https://doi.org/10.1182/blood.V114.22.4805.4805

Published: 2009

Journal Articles

GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib

Johann Kern, Gerold Untergasser, Christoph Zenzmaier, Bettina Sarg, Guenther Gastl, Eberhard Gunsilius, Michael Steurer

Blood (2009) 114 (18): 3960–3967.

https://doi.org/10.1182/blood-2009-03-209668

Published: 2009

Includes: Supplemental data

Journal Articles

Anti-Angiogenic Activity of Bortezomib Is blocked by a 50–60 KDa Protein Secreted by Various tumor Cell Lines

Johann Kern, Gerold Untergasser, PhD, Heinz Zoller, MD, Gunther Gastl, Eberhard Gunsilius, M.D., Michael Steurer, MD

Blood (2008) 112 (11): 5448.

https://doi.org/10.1182/blood.V112.11.5448.5448

Published: 2008

Journal Articles

Vasohibin Inhibits Large Blood Vessel Formation and Supports Development of Microvessels

Johann Kern, Michael Steurer, Gunther Gastl, Eberhard Gunsilius, Gerold Untergasser

Blood (2008) 112 (11): 5450.

https://doi.org/10.1182/blood.V112.11.5450.5450

Published: 2008

Journal Articles

Cytotoxic Activity of the Proteasome Inhibitor MLN-273 but Not of Bortezomib Is Inhibited by MDR1.

Holger Rumpold, MD, Anna M. Wolf, MD, Gerold Untergasser, PhD, Guenther Gastl, MD, Eberhard Gunsilius, MD, Dominik Wolf, MD

Blood (2005) 106 (11): 4467.

https://doi.org/10.1182/blood.V106.11.4467.4467

Published: 2005

Journal Articles

Human Endothelial Cells Generated In Vitro from Circulating Progenitors Represent a Safe Tool for Targeting of Myocardial Tissue.

Ruth Koeck, Dominik G.F. Wolf, MD, Holger F. Rumpold, MD, Harald Ott, MD, Gerold Untergasser, MD, Martin Erdel, PhD, Paul Debagge, MD, Guenther A. Gastl, MD, Eberhard Gunslius, MD

Blood (2004) 104 (11): 4138.

https://doi.org/10.1182/blood.V104.11.4138.4138

Published: 2004

NARROW

GRP-78 Secreted by Tumor Cells Blocks the Anti-Angiogenic Activity of Bortezomib.

GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib

Anti-Angiogenic Activity of Bortezomib Is blocked by a 50–60 KDa Protein Secreted by Various tumor Cell Lines

Vasohibin Inhibits Large Blood Vessel Formation and Supports Development of Microvessels

Cytotoxic Activity of the Proteasome Inhibitor MLN-273 but Not of Bortezomib Is Inhibited by MDR1.

Human Endothelial Cells Generated In Vitro from Circulating Progenitors Represent a Safe Tool for Targeting of Myocardial Tissue.

Email alerts

ASH Publications

American Society of Hematology

GRP-78 Secreted by Tumor Cells Blocks the Anti-Angiogenic Activity of Bortezomib.

GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib

Anti-Angiogenic Activity of Bortezomib Is blocked by a 50–60 KDa Protein Secreted by Various tumor Cell Lines

Vasohibin Inhibits Large Blood Vessel Formation and Supports Development of Microvessels

Cytotoxic Activity of the Proteasome Inhibitor MLN-273 but Not of Bortezomib Is Inhibited by MDR1.

Human Endothelial Cells Generated In Vitro from Circulating Progenitors Represent a Safe Tool for Targeting of Myocardial Tissue.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only